Skip to main
KRRO

KRRO Stock Forecast & Price Target

KRRO Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Korro Bio is poised for potential success with KRRO-121, as it has a strong pipeline of disease-modifying treatments for rare and prevalent diseases. The company's innovative approach to RNA editing technology offers a precise and tunable solution to treat a range of disorders. Additionally, Korro Bio has a clear clinical and regulatory path for their therapies, giving investors confidence in their potential success.

Bears say

Korro Bio is a clinical-stage biopharmaceutical company with a portfolio of programs that are designed to harness the body's natural RNA editing process to treat rare and highly prevalent diseases. Their lead asset, KRRO-121, is a GalNAc-ASO designed to reduce hyperammonemia in urea cycle disorder (UCD) and hepatic encephalopathy (HE) by stabilizing glutamine synthetase (GS). While the company has presented compelling preclinical data and has a clear regulatory path established for HE, there are financial risks associated with their development stage and the need for additional funding. Additionally, the company's lead product may face challenges in achieving widespread adoption due to the difficulty in managing UCD and potential competition from other treatments. As such, the company's financial outlook is uncertain and it may face challenges in achieving their projected targets.

KRRO has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Frequency Therapeutics Inc (KRRO) Forecast

Analysts have given KRRO a Buy based on their latest research and market trends.

According to 8 analysts, KRRO has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Frequency Therapeutics Inc (KRRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.